How can European countries improve cervical cancer prevention for women?
Exploring the value of a rapid, on-demand test for the detection of human papillomavirus
Estimating the true costs of splitting HIV antiretroviral drugs
There is a temptation to switch to cheaper generic antiretroviral drugs compared to fixed-dose combination therapy for HIV patients in the interests of cost savings. However, in our analysis we found that there were no costs saved when including all patient care including drugs, additional clinic visits and monitoring. We also found that switching may cause confusion for some patients, risking loss of adherence. This evidence can help commissioners make better policy decisions about drug provision.
Increased efficiency and improved treatment for stable HIV patients in England
Collaborators at St Georges Hospital wanted to understand the impact of changing service provision for stable HIV patients, as no evidence existed on what was best for clinics. We built a tool in Excel, and results indicated that 6-monthly appointments and 3-monthly home delivery of drugs is the cheapest option and could yield £2000 savings per patient, translating to an annual cost reduction of ~£8 million for the estimated 4000 eligible patients not currently on home delivery in England in 2012.
The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study
The cost and tariff reimbursement of idiopathic pulmonary fibrosis in England
Treatment for stable HIV patients in England: can we save costs and improve patient care?
The cost-effectiveness of point of care tests for chlamydia and gonorrhoeae in sexual health clinics
Cost effectiveness of screening for Chlamydia trachomatis in Ireland
What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia?
